Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is lim...

Descripción completa

Detalles Bibliográficos
Autores: Almeida, Antonio M., Prebet, Thomas, Itzykson, Raphael, Ramos, Fernando, Al-Ali, Haifa, Shammo, Jamile, Pinto, Ricardo, Maurillo, Luca, Wetzel, Jaime, Musto, Pellegrino, Van De Loosdrecht, Arjan A., Costa, Maria Joao, Esteves, Susana, Burgstaller, Sonja, Stauder, Reinhard, Autzinger, Eva M., Lang, Alois, Krippl, Peter, Geissler, Dietmar, Falantes, Jose F., Pedro, Carmen, Bargay Lleonart, Joan, Deben, Guillermo, Garrido, Ana, Bonanad, Santiago, Diez-Campelo, Maria, Thepot, Sylvain, Ades, Lionel, Sperr, Wolfgang R., Valent, Peter, Fenaux, Pierre, Sekeres, Mikkael A., Greil, Richard, Pleyer, Lisa
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/9895
Acceso en línea:https://hdl.handle.net/20.500.13003/9895
Access Level:acceso abierto
Palabra clave:Decitabine
Female
Proportional Hazards Models
Retrospective Studies
Leukemia, Erythroblastic, Acute
Aged, 80 and over
Aged
Bone Marrow
Azacitidine
Male
Humans
Cytogenetic Analysis
Antineoplastic Combined Chemotherapy Protocols
Middle Aged
Biomarkers
Survival Analysis
Adult
Treatment Outcome
Leucemia Eritroblástica Aguda
Modelos de Riesgos Proporcionales
Resultado del Tratamiento
Biomarcadores
Análisis Citogenético
Análisis de Supervivencia
Femenino
Decitabina
Masculino
Azacitidina
Humanos
Persona de Mediana Edad
Protocolos de Quimioterapia Combinada Antineoplásica
Anciano
Anciano de 80 o más Años
Médula Ósea
Estudios Retrospectivos
Adulto
acute erythroleukemia
azacitidine
decitabine
Descripción
Sumario:Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p <= 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.

Similares en LA Referencia